Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Chemoradiotherapy in LANPC
NCT04870905Phase 2Not yet recruiting
- Sponsor
- Cancer Center of Guangzhou Medical University
- Start
- Mar 2023
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in nasopharyngeal carcinoma (NPC), sponsored by Cancer Center of Guangzhou Medical University. Planned start Mar 2023; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04870905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04870905.